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Statement of Translational Relevance << Word count:133, including spaces [limit: 150]>> 102 
Nivolumab is a programmed death-1 inhibitor approved for the treatment of recurrent/metastatic 103 
squamous cell carcinoma of the head and neck (SCCHN) post-platinum therapy. In the first-line 104 
setting for recurrent/metastatic SCCHN, cetuximab as part of the platinum-based EXTREME 105 
regimen is a common treatment option. Cetuximab modulates immune responses and may 106 
affect the efficacy of subsequent immunotherapy. In this post hoc analysis of the randomized 107 
phase III CheckMate 141 trial in recurrent/metastatic SCCHN post-platinum therapy, nivolumab 108 
appeared to prolong overall survival versus investigator’s choice of therapy in patients with and 109 
without prior cetuximab exposure; reduction in risk of death with nivolumab was 16% and 48%, 110 
respectively. Safety in both subgroups was similar to the overall population. Prospective 111 
randomized clinical trials could help elucidate the impact of prior cetuximab treatment on the 112 
efficacy of subsequent immunotherapy.   113 
Research. 
on June 3, 2020. © 2019 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 25, 2019; DOI: 10.1158/1078-0432.CCR-18-3944 
  Ferris et al. Clin Cancer Res 
   
Page 6 of 28 
 
Abstract (word limit: 250; current count: 249) 114 
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of 115 
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab 116 
exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head 117 
and neck (SCCHN) who had experienced progression within 6 months of platinum-containing 118 
chemotherapy. 119 
Patients and Methods: In the randomized, open-label, phase III CheckMate 141 trial, 120 
patients were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator’s choice (IC) 121 
of single-agent chemotherapy, with stratification by prior cetuximab exposure. The primary 122 
endpoint was overall survival (OS); additional endpoints were progression-free survival, 123 
objective response rate, and safety.  124 
Results: In patients with prior cetuximab exposure, the median OS was 7.1 months with 125 
nivolumab versus 5.1 months with IC (HR, 0.84; 95% CI, 0.62–1.15); OS benefit with nivolumab 126 
was maintained across most demographic subgroups. In patients without prior cetuximab 127 
exposure, the median OS was 8.2 months with nivolumab versus 4.9 months with IC (HR, 0.52; 128 
95% CI, 0.35–0.77); OS benefit with nivolumab was maintained across patient baseline 129 
subgroups including tumor programmed death ligand 1 (PD-L1) expression (<1% or ≥1%). 130 
Grade 3–4 treatment-related adverse event rates favored nivolumab versus IC in both 131 
subgroups.  132 
Conclusions: Nivolumab appeared to improve efficacy versus IC regardless of prior 133 
cetuximab use, supporting its use in patients with R/M SCCHN with or without prior cetuximab 134 
exposure. The reduction in risk of death with nivolumab compared with IC was greater in 135 
patients without prior cetuximab exposure versus with prior cetuximab exposure.   136 
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Introduction 137 
Until recently, patients with platinum-refractory recurrent or metastatic (R/M) squamous 138 
cell carcinoma of the head and neck (SCCHN) had poor prognosis and limited options besides 139 
cetuximab monotherapy (1). In 2016, two programmed death-1 (PD-1) inhibitors, nivolumab and 140 
pembrolizumab, were approved for the treatment of patients with R/M SCCHN who experienced 141 
disease progression after platinum-based therapy (2, 3). 142 
 Cetuximab targets the epidermal growth factor receptor (EGFR) and may interrupt 143 
oncogene signaling in tumors that have become oncogene-addicted; it can also result in 144 
induction of innate and adaptive immune responses and downregulation of immunosuppressive 145 
mechanisms (4-7). Cetuximab-mediated EGFR blockade has been shown to downregulate 146 
interferon γ-induced programmed death ligand 1 (PD-L1) expression in SCCHN, which may 147 
signify restoration of the antitumor immune response (8, 9). Cetuximab drives antibody-148 
dependent cellular cytotoxicity of natural killer (NK) cells as well as maturation and crosstalk 149 
between NK and dendritic cells. However, cetuximab has also been shown to promote 150 
expansion of immunosuppressive regulatory T cells in the tumor microenvironment (6). 151 
Additionally, it has been shown that after cetuximab monotherapy, the cytolytic activity of 152 
activated CD8+ T cells is suppressed through the increase and coexpression of PD-1 and TIM-3 153 
in the tumor microenvironment (10). Cetuximab-activated NK cells also secrete cytokines which 154 
enhance antigen presentation (11). The resulting chronic antigen stimulation leads to 155 
upregulation of immune checkpoint receptors associated with T cell exhaustion (such as CTLA-156 
4, TIM-3 and TGF-ß), creating a negative feedback loop (12). Thus, those patients who 157 
progress after cetuximab therapy have likely been selected for expansion of suppressive cell 158 
types (regulatory T cells, myeloid-derived suppressor cells) and might be less likely to respond 159 
to immunotherapy (6, 13). A schematic summarizing stimulatory and suppressive changes that 160 
may occur in the microenvironment in patients treated with cetuximab is shown in Fig. 1.  161 
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 CheckMate 141 was a phase III study that investigated nivolumab versus investigator’s 162 
choice (IC) of therapy in patients with R/M SCCHN who had experienced tumor progression or 163 
recurrence within 6 months of platinum-based chemotherapy in the locally advanced (i.e., with 164 
radiation), recurrent, or metastatic setting. Patient randomization was stratified by prior 165 
cetuximab exposure to minimize imbalance in treatment arms due to the reported immune-166 
modulatory effects of cetuximab.(11) Nivolumab significantly improved survival versus IC in the 167 
overall study population at the primary analysis with a potential advantage noted among 168 
patients without prior cetuximab exposure (14). Efficacy at 1-year and 2-year follow-up were 169 
consistent with results from the primary analysis (15, 16). Nivolumab also stabilized quality of 170 
life compared with IC (17). Here, we analyzed the effects of prior cetuximab exposure, a 171 
prespecified stratification factor, on outcomes in CheckMate 141.  172 
 173 
Methods 174 
As described previously, CheckMate 141 was a randomized, open-label, phase III study 175 
in patients with histologically confirmed R/M stage III/IV SCCHN of the oral cavity, pharynx, or 176 
larynx that had progressed within 6 months of platinum-containing chemotherapy (14). Patients 177 
were randomized (2:1) to receive nivolumab (3 mg/kg intravenously [IV] every 2 weeks) or IC, 178 
consisting of methotrexate (40–60 mg/m2 IV weekly), docetaxel (30–40 mg/m2 IV weekly), or 179 
cetuximab (400 mg/m2 IV once, then 250 mg/m2 weekly), with stratification by prior cetuximab 180 
use. Patients continued treatment until disease progression, unacceptable toxicity, or withdrawal 181 
of consent.  182 
The primary endpoint was overall survival (OS); secondary endpoints were progression-183 
free survival and objective response rate (ORR) (14). Tumor response was assessed per 184 
Response Evaluation Criteria In Solid Tumors v1.1 at baseline, week 9, and every 6 weeks 185 
thereafter (18). Patients were followed up for survival during treatment and every 3 months after 186 
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discontinuation. Safety was monitored throughout treatment and for 100 days after 187 
administration of last dose. Assessment of tumor PD-L1 expression and human papillomavirus 188 
(HPV) status has been described previously (14).   189 
The association of immune cell phenotypes with clinical response was assessed as an 190 
exploratory endpoint. Peripheral blood lymphocyte samples were collected at baseline and on 191 
day 43 of treatment and analyzed by flow cytometry. CD8+ effector T cells were defined as 192 
TCRalpha/beta+CD8+CCR7−CD45RA+ and regulatory T cells as CD4+CD25hiCD127loFoxP3+. 193 
For this analysis, responders were defined as patients with complete or partial response and 194 
nonresponders as patients with stable or progressive disease.  195 
CheckMate 141 was conducted in accordance with the ethical principles of the 196 
Declaration of Helsinki. Written informed consent was obtained from all patients prior to 197 
enrollment. The study was approved by the institutional review board or independent ethics 198 
committee at each center and was conducted in accordance with Good Clinical Practice 199 
guidelines defined by the International Conference on Harmonisation. 200 
 201 
 202 
Statistical analyses 203 
Efficacy (in all randomized patients) and safety (in patients who received at least one 204 
dose of treatment) have been reported previously (14). The present analysis of outcomes by 205 
cetuximab exposure is based on a September 2016 database lock, representing a minimum 206 
follow-up of 11.4 months.  207 
 Survival analyses were performed using the Kaplan-Meier method. HRs and confidence 208 
intervals (CIs) were estimated using a Cox proportional hazards model. Prespecified analyses 209 
were conducted to evaluate treatment effects by tumor PD-L1 expression and HPV status. A 210 
Cox regression was performed to investigate the association between OS and a set of predictor 211 
variables including age, Eastern Cooperative Oncology Group performance status (ECOG PS), 212 
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prior radiotherapy, prior surgery, prior docetaxel/paclitaxel/taxane, number of prior lines of 213 
systemic therapy, region, tumor PD-L1 expression, HPV status, prior cetuximab, as well as the 214 
interaction of prior cetuximab exposure with ECOG PS, tumor PD-L1 expression, and HPV 215 
status (14). 216 
 A two-way analysis of variance with Šidák multiple comparisons test correction was 217 
computed to descriptively analyze peripheral blood lymphocyte biomarker levels between 218 
responders and nonresponders. 219 
BMS policy on data sharing may be found at https://www.bms.com/researchers-and-220 
partners/independent-research/data-sharing-request-process.html. 221 
 222 
Results  223 
Patients and treatment 224 
Of 361 randomized patients, 147 of 240 patients in the nivolumab arm (61.3%) and 74 of 121 in 225 
the IC arm (61.2%) had previously received cetuximab (Supplementary Fig. S1). Among 226 
patients with prior cetuximab exposure randomized to the IC arm, 41 (55.4%), 32 (43.2%), and 227 
1 (1.4%) received methotrexate, docetaxel, and cetuximab, respectively. Among patients 228 
without prior cetuximab exposure, the distribution was 11 (23.4%), 22 (46.8%), and 14 (29.8%) 229 
patients, respectively.  230 
 Baseline characteristics were similar between patients with and without prior cetuximab 231 
exposure, with a few exceptions (Table 1). Of note, patients with prior cetuximab exposure were 232 
heavily pretreated, with 69.7% in both treatment arms having received at least two prior lines of 233 
therapy. Among patients without prior cetuximab exposure, only 30.7% across both treatment 234 
arms had received at least two prior lines of therapy. A summary of treatments received by 235 
patients prior to enrollment in CheckMate 141 is included in Supplementary Tables S1 and S2. 236 
Patients with prior cetuximab had slightly higher exposure to taxanes and fluorouracil compared 237 
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with patients without prior cetuximab exposure in both treatment arms. Details of cetuximab-238 
containing regimens received by patients are summarized in Supplementary Table S3. 239 
 240 
Survival 241 
In patients with prior cetuximab exposure, the median OS was 7.1 months with 242 
nivolumab versus 5.1 months with IC (HR = 0.84; 95% CI, 0.62–1.15). In patients without prior 243 
cetuximab exposure, the median OS was 8.2 months versus 4.9 months, respectively (HR = 244 
0.52; 95% CI, 0.35–0.77; Fig. 2A and 2B). Estimated 12-month OS rates were higher with 245 
nivolumab versus IC in both groups: 31.3% (95% CI, 23.9–38.9) versus 25.4% (95% CI, 16.0–246 
35.8) in patients with prior cetuximab exposure and 38.5% (95% CI, 28.6–48.3) and 11.0% 247 
(95% CI, 4.0–21.9) in patients without prior cetuximab exposure.  248 
 In patients without prior cetuximab exposure, HR estimates for death among patient 249 
baseline subgroups were consistent with the overall treatment effect (Fig. 2C). In this patient 250 
population, median OS was longer for nivolumab versus IC regardless of HPV status, with the 251 
greatest benefit observed in patients with HPV-positive tumors (median OS: 15.6 vs. 3.1 252 
months). Median OS was also longer for nivolumab versus IC in patients without prior 253 
cetuximab exposure and tumor PD-L1 expression ≥1% (PD-L1 expressors) and <1% (PD-L1 254 
non-expressors), and those with only one line of prior therapy. Among patients with prior 255 
cetuximab exposure, nivolumab extended median OS versus IC across most demographic 256 
subgroups. 257 
 In the Cox regression analysis for OS, adjusted 95% CIs for HRs did not include 1 for 258 
prior radiotherapy, region (Europe vs. North America), ECOG PS with prior cetuximab, PD-L1 259 
expression with prior cetuximab exposure, HPV (negative vs. positive) without prior cetuximab 260 
exposure, and HPV (unknown vs. positive) without prior cetuximab exposure (Table 2). For all 261 
other variables listed in Table 2, including number of prior lines of systemic therapy, the 262 
adjusted 95% CIs for HRs included 1. 263 
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 Consistent with the overall study population, median progression-free survival was 264 
similar in both treatment arms in patients with (nivolumab = 2.0 months; IC = 2.1 months; HR = 265 
0.86; 95% CI, 0.63–1.18) and without (nivolumab = 2.2 months; IC = 2.6 months; HR = 0.89; 266 
95% CI, 0.60–1.31) prior cetuximab exposure.  267 
 268 
Best overall response 269 
Nivolumab resulted in higher ORR versus IC in patients with and without prior cetuximab 270 
exposure, with odds ratios of 1.69 (0.59–4.80) and 4.68 (1.03–21.28), respectively (Table 3). In 271 
the nivolumab and IC arms, ORRs were 10.9% and 6.8% (prior cetuximab) and 17.2% and 272 
4.3% (no prior cetuximab), respectively. In the nivolumab arm, the median duration of response 273 
was 9.7 months (prior cetuximab) and not reached (no prior cetuximab).  274 
 Among patients with prior cetuximab exposure, ORR was higher with nivolumab versus 275 
IC in PD-L1 expressors (15.4% vs. 2.5%) but not in PD-L1 non-expressors (8.0% vs. 15.0%). 276 
Among patients without prior cetuximab exposure, nivolumab improved ORR versus IC 277 
irrespective of tumor PD-L1 expression: 19.4% versus 0% (PD-L1 expressors) and 21.7% 278 
versus 5.6% (PD-L1 non-expressors). In the nivolumab arm, 16 patients in each of the groups 279 
(with prior cetuximab, 10.9%; without prior cetuximab, 17.2%) had >30% reduction in target 280 
lesions (Supplementary Fig. S2). 281 
 282 
Safety 283 
Among patients with prior cetuximab exposure, any grade and grade 3–4 treatment-284 
related adverse events were reported in 57.9% and 13.1% of patients (nivolumab) and 80.3% 285 
and 42.4% of patients (IC), respectively (Supplementary Table S4). Among patients without 286 
prior cetuximab exposure, the respective rates were 68.1% and 18.7% (nivolumab) and 77.8% 287 
and 26.7% (IC). The only grade 3–4 select treatment-related adverse events reported in more 288 
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than one patient were pulmonary-related events in 2 of 145 (1.4%) patients with prior cetuximab 289 
exposure in the nivolumab arm (Supplementary Table S5).  290 
 291 
Circulating immune cell phenotypes  292 
Among patients without prior cetuximab exposure who received nivolumab, responders 293 
(n = 9) had higher levels of total CD8+ T cells and lower levels of PD-1+ CD8+ effector T cells 294 
than nonresponders (n = 11) at baseline and on day 43 (Fig. 3A). In this group, levels of PD-1+ 295 
regulatory T cells were lower in responders (n = 9) than nonresponders (n = 11) at both time 296 
points (Fig. 3B). Similar trends were observed in patients with prior cetuximab exposure 297 
receiving nivolumab.  298 
 Frequencies of CD4+, TIM-3+, CTLA-4+, LAG-3+, CD39+, or Nrp-1+ regulatory T cells 299 
were similar between responders and nonresponders in the nivolumab arm, irrespective of prior 300 
cetuximab exposure. Immune cell subtype levels were also similar in patients with or without 301 
prior cetuximab exposure receiving IC. Owing to insufficient specimens, analyses by HPV status 302 
or other subgroup analyses could not be performed. 303 
 304 
Discussion 305 
In this analysis of CheckMate141, nivolumab appeared to improve clinical outcomes 306 
versus IC regardless of prior cetuximab exposure. The OS benefit with nivolumab versus IC was 307 
maintained at 2-year follow-up, with HR (95% CI) of 0.79 (0.59, 1.06) in patients with prior 308 
cetuximab exposure and 0.52 (0.36, 0.76) in patients without prior cetuximab exposure (15). 309 
Nivolumab was well tolerated versus IC, regardless of prior cetuximab use, and its safety profile 310 
in both groups of patients was similar to that of the overall population. 311 
  Cetuximab modulates the PD-1 axis, and prior cetuximab exposure could potentially 312 
affect outcomes with nivolumab (4-6, 9). Cetuximab has been shown to significantly 313 
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downregulate interferon γ-induced PD-L1 expression in head and neck tumor cell lines (9). In 314 
CheckMate 141, tumor PD-L1 expression (<1% and ≥1%) was similar in patients with and 315 
without prior cetuximab exposure, indicating that differences in response to nivolumab between 316 
these patient groups may not be related to the effect of cetuximab on tumor PD-L1 expression. 317 
Cetuximab may also induce regulatory T cells, particularly in nonresponders (6). While further 318 
studies are needed, one hypothesis is that the above effect could potentially predispose patients 319 
who experienced recurrence after prior cetuximab exposure to exhibit lower clinical benefit to 320 
immunotherapeutic strategies than those not previously exposed to cetuximab. 321 
 Owing to small sample sizes, statistical significance is not reported for the exploratory 322 
immune cell biomarker analysis. Nonetheless, differences in levels of total CD8+ T cells and PD-323 
1+ CD8+ effector T cells, and PD-1+ regulatory T cells were noted among responders and 324 
nonresponders, primarily in patients without prior cetuximab exposure. In particular, higher 325 
levels of total CD8+ T cells at baseline were associated with better response, as were lower 326 
levels of CD8+ PD-1+ effector T cells, the latter associated with T cell exhaustion. These findings 327 
were more pronounced in patients without prior cetuximab exposure, raising the possibility that 328 
cetuximab modulates the CD8 T cell compartment, as previously suggested (6, 8, 9). While 329 
these results have potential prognostic value, the analysis was exploratory and additional 330 
research is warranted. 331 
To our knowledge, this is the first detailed published report on the effect of prior 332 
cetuximab exposure on response to a PD-1 inhibitor. A post hoc analysis of the phase III 333 
KEYNOTE-040 evaluating pembrolizumab in R/M SCCHM was recently published (19). Our 334 
analysis provides insights on the potential impact of prior cetuximab exposure on efficacy of 335 
subsequent nivolumab treatment; however, CheckMate 141 was not powered to detect 336 
significant differences between patients with and without cetuximab exposure. Another limitation 337 
of the current analysis is that data on timing of the prior cetuximab treatment relative to on-338 
treatment study were not available. Additionally, information on whether prior cetuximab was 339 
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administered in combination with radiation, and consequently, the context for treatment, was 340 
also not available. Prospective randomized phase III clinical trials could help assess the impact 341 
of prior cetuximab exposure on the efficacy of subsequent immunotherapy. For example, 342 
comparison of efficacy among patients with prior cetuximab exposure randomized to treatment 343 
with nivolumab versus IC and stratified by prior cisplatin exposure (to standardize prior lines of 344 
therapy) could yield useful results. Alternatively, efficacy could be compared among patients 345 
with prior exposure to the EXTREME regimen who are randomized to receive treatment with 346 
nivolumab versus IC.  347 
Recently, data have been published on the utility of cetuximab plus radiation in the 348 
treatment of in certain patient populations (eg, HPV-positive oropharyngeal cancer, elderly) with 349 
locally advanced SCCHN (20-22). Additionally, results on the first-line treatment of 350 
recurrent/metastatic SCCHN with pembrolizumab have been published (23). These emerging 351 
data underscore the need to optimize the treatment approach for SCCHN based on patient and 352 
disease characteristics with the goal of maximizing options for patients. To that end, the data 353 
presented in this manuscript may be relevant in informing decisions with regard to sequencing 354 
of therapy in patients with SCCHN. 355 
In the present analysis, reduction in risk of death with nivolumab was 16% in patients 356 
with prior cetuximab exposure and 48% in patients without prior cetuximab use. In the first-line 357 
setting for R/M disease, cetuximab as part of the EXTREME regimen has been the preferred 358 
option for patients with ECOG PS of 0–1 (24). Therefore, patients without prior cetuximab 359 
exposure in CheckMate 141 may not yet have received treatment for R/M disease. Indeed, 360 
among patients without prior cetuximab exposure, 69% had only one prior line of therapy, 361 
whereas patients with prior cetuximab were heavily pretreated with 70% having undergone two 362 
or more prior lines of therapy. However, a Cox regression analysis identified that the number of 363 
prior lines of systemic therapy was a nonsignificant predictor of OS in the nivolumab arm.  364 
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The lower efficacy in the IC arm among patients without prior cetuximab exposure could 365 
potentially be attributed to patient and/or disease characteristics, or choice of therapy. ECOG 366 
PS, however, was similar among patients with and without prior cetuximab exposure, with 367 
16.2% and 23.4%, respectively, having a PS of 0. The proportions of patients receiving 368 
docetaxel as IC therapy were balanced between patients with (43%) and without (47%) prior 369 
cetuximab exposure. The use of methotrexate and cetuximab as IC therapy was more variable: 370 
among patients with prior cetuximab exposure, all but one of the remaining patients (55%) 371 
received methotrexate, whereas among patients without prior cetuximab exposure, 23% 372 
received methotrexate and 30% received cetuximab. The design of the study precluded 373 
assessing efficacy of nivolumab versus the individual agents used in IC. Qualitatively, however, 374 
treatment with methotrexate had better outcomes than with cetuximab (14). This may have 375 
contributed to the reduced efficacy of the IC arm among patients without prior cetuximab 376 
exposure.  377 
 With regard to tumor PD-L1 expression and HPV status, among patients with prior 378 
cetuximab exposure, nivolumab improved ORR and OS versus IC in PD-L1 expressors only, 379 
and no consistent association was noted between HPV status and efficacy. Among patients 380 
without prior cetuximab exposure, response rates were higher with nivolumab versus IC 381 
regardless of PD-L1 expression or HPV status. These results may be more of a reflection of the 382 
overall better performance of patients without prior cetuximab exposure and the poor 383 
performance of the IC arm rather than any underlying biology. 384 
Overall, findings from this post hoc analysis of clinical outcomes of the CheckMate 141 385 
study are consistent with results from the primary analysis and support the use of nivolumab 386 
across a broad population of patients with R/M SCCHN post-platinum therapy. The reduction in 387 
the risk of death with nivolumab compared with IC was higher in patients without prior 388 
cetuximab exposure, and prognostic biomarker assessments were promising in this patient 389 
population. Further research is needed to optimize treatment sequence in SCCHN in order to 390 
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maximize therapy options and to understand the impact of prior treatments on response to PD-1 391 
inhibitors; studies are underway to assess nivolumab combinations, including with cetuximab 392 
and radiotherapy (25).  393 
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Tables  504 
 505 
Table 1. Characteristics at baseline by prior cetuximab exposure 506 
Characteristic  Patients with prior exposure to 
cetuximab 
 
Patients without prior exposure to 
cetuximab 
 Nivolumab 
(n = 147) 
IC 
(n = 74) 
Total 
(n = 221) 
 
Nivolumab 
(n = 93) 
IC 
(n = 47) 
Total 
(n = 140) 
Age, median (range), years  60 (31–83) 62 (32–78) 60 (31–83)  59 (29–79) 59 (28–78) 59 (28–79) 
≥65 years, n (%)  39 (26.5) 28 (37.8) 67 (30.3)  29 (31.2) 17 (36.2) 46 (32.9) 
ECOG PS, n (%)         
0  29 (19.7) 12 (16.2) 41 (18.6)  20 (21.5) 11 (23.4) 31 (22.1) 
1  116 (78.9) 59 (79.7) 175 (79.2)  73 (78.5) 35 (74.5) 108 (77.1) 
2  1 (0.7) 2 (2.7) 3 (1.4)  0 1 (2.1) 1 (0.7) 
Not reported  1 (0.7) 1 (1.4) 2 (0.9)  0 0 0 
Site of primary tumor, n (%)         
Oral cavity  62 (42.2)  42 (56.8) 104 (47.1)  46 (49.5)  25 (53.2) 71 (50.7) 
Pharynx  59 (40.1)  22 (29.7) 81 (36.7)  33 (35.5)  15 (31.9) 48 (34.3) 
Larynx  24 (16.3)  9 (12.2) 33 (14.9)  10 (10.8)  5 (10.6) 15 (10.7) 
Other  2 (1.4)  1 (1.4) 3 (1.4)  4 (4.3)  2 (4.3) 6 (4.3) 
Region, n (%)         
North America  57 (38.8) 26 (35.1) 83 (37.6)  44 (47.3) 18 (38.3) 62 (44.3) 
Europe  75 (51.0) 39 (52.7) 114 (51.6)  34 (36.6) 23 (48.9) 57 (40.7) 
Rest of world  15 (10.2) 9 (12.2) 24 (10.9)  15 (16.1) 6 (12.8) 21 (15.0) 
Tobacco use, n (%)         
Current/former  118 (80.3) 53 (71.6) 171 (77.4)  73 (78.5) 33 (70.2) 106 (75.7) 
Never  22 (15.0) 18 (24.3) 40 (18.1)  17 (18.3) 13 (27.7) 30 (21.4) 
Unknown  7 (4.8) 3 (4.1) 10 (4.5)  3 (3.2) 1 (2.1) 4 (2.9) 
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HPV status, n (%)         
Positive  36 (24.5) 18 (24.3) 54 (24.4)  27 (29.0) 11 (23.4) 38 (27.1) 
Negative  33 (22.4) 20 (27.0) 53 (24.0)  22 (23.7) 17 (36.2) 39 (27.9) 
Unknown  1 (0.7) 2 (2.7) 3 (1.4)  1 (1.1) 0 1 (0.7) 
Not reported  77 (52.4) 34 (45.9) 111 (50.2)  43 (46.2) 19 (40.4) 62 (44.3) 
Tumor PD-L1 expression, n 
(%) 
 
       
≥1% (PD-L1 expressors)  52 (35.4) 40 (54.1) 92 (41.6)  36 (38.7) 21 (44.7) 57 (40.7) 
<1% (PD-L1 non-
expressors) 
 
50 (34.0) 20 (27.0) 70 (31.7)  23 (24.7) 18 (38.3) 41 (29.3) 
Not quantifiable  45 (30.6) 14 (18.9) 59 (26.7)  34 (36.6) 8 (17.0) 42 (30.0) 
Lines of prior systemic 
cancer therapy, n (%) 
 
       
1  44 (29.9) 23 (31.1) 67 (30.3)  62 (66.7) 35 (74.5) 97 (69.3) 
2  57 (38.8) 32 (43.2) 89 (40.3)  23 (24.7) 12 (25.5) 35 (25.0) 
≥3  46 (31.3) 19 (25.7) 65 (29.4)  8 (8.6) 0 8 (5.7) 
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; HPV, human papillomavirus; IC, investigator’s 507 
choice; PD-L1, programmed death ligand 1.  508 
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Table 2. Cox regression analysis for overall survival in the nivolumab arm 
Effect HR 95% CI 
Age (≥65 years vs. <65 years)  1.196 0.844–1.695 
Prior radiotherapy (yes vs. no) 1.747 1.022–2.988 
Prior surgery (yes vs. no)  1.295 0.780–2.149 
Prior docetaxel/paclitaxel/taxane (yes vs. no)  1.278 0.915–1.784 
Number of prior lines of systemic therapy (1 vs. ≥2)  1.238 0.887–1.728 
Region (Europe vs. North America)  1.562 1.093–2.231 
Region (rest of world vs. North America)  0.831 0.474–1.460 
ECOG PS (≥1 vs. 0) (prior cetuximab = yes) 
ECOG PS (≥1 vs. 0) (prior cetuximab = no)  
3.715 
0.859 
2.047–6.742 
0.445–1.658 
Tumor PD-L1 expression (≥1% vs. <1%) (prior cetuximab = yes) 
Tumor PD-L1 expression (≥1% vs. <1%) (prior cetuximab = no) 
0.592 
1.112 
0.375–0.935 
0.567–2.180 
HPV status (negative vs. positive) (prior cetuximab = yes) 
HPV status (negative vs. positive) (prior cetuximab = no) 
0.671 
2.304 
0.383–1.176 
1.076–4.931 
HPV status (unknown vs. positive) (prior cetuximab = yes) 
HPV status (unknown vs. positive) (prior cetuximab = no) 
0.762 
2.885 
0.479–1.211 
1.445–5.761 
Variables for which the adjusted 95% CI for HR did not include 1 are shown in bold. 509 
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status;  510 
HPV, human papillomavirus; PD-L1, programmed death ligand 1.511 
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Table 3. Response evaluation by prior cetuximab exposure 512 
 
 Patients with prior exposure to cetuximab  Patients without prior exposure to 
cetuximab 
 Nivolumab 
(n = 147) 
IC 
(n = 74) 
 Nivolumab 
(n = 93) 
IC 
(n = 47) 
Best overall response, n (%)       
Complete response  2 (1.4) 1 (1.4)  4 (4.3) 0 
Partial response  14 (9.5) 4 (5.4)  12 (12.9) 2 (4.3) 
Stable disease  30 (20.4) 22 (29.7)  25 (26.9) 21 (44.7) 
Progressive disease  65 (44.2) 29 (39.2)  35 (37.6) 13 (27.7) 
Unable to determine  36 (24.5) 18 (24.3)  17 (18.3) 11 (23.4) 
ORR, n (%)  16 (10.9) 5 (6.8)  16 (17.2) 2 (4.3) 
[95% CI]  [6.4–17.1] [2.2–15.1]  [10.2–26.4] [0.5–14.5] 
Odds ratio (95% CI)  1.69 (0.59–4.80)  4.68 (1.03–21.28) 
ORR by HPV status, n (%)       
Positive  2 (5.6) 1 (5.6)  8 (29.6) 0 
Negative  3 (9.1) 2 (10.0)  5 (22.7) 2 (11.8) 
Unknown  11 (14.1) 2 (5.6)  3 (7.0) 0 
ORR by tumor PD-L1 expression, n (%)       
≥1% (PD-L1 expressors)  8 (15.4) 1 (2.5)  7 (19.4) 0 
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<1% (PD-L1 non-expressors)   4 (8.0) 3 (15.0)  5 (21.7) 1 (5.6) 
Not quantifiable  4 (8.9) 1 (7.1)  4 (11.8) 1 (12.5) 
Duration of response, median, months  9.7 3.0  NR NR 
Range  2.8+ to 16.5+ 1.5+ to 3.0  2.8- to 20.3+ 4.9 to 8.5+ 
Abbreviations: CI, confidence interval; HPV, human papillomavirus; IC, investigator’s choice; NR, not reached; ORR, objective response rate; PD-L1, programmed death ligand 1. 513 
  514 
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Figure Legends 515 
Figure 1. Immune activity mediated by cetuximab in the SCCHN tumor microenvironment. 516 
Binding of cetuximab to EGFR recruits CD8+ T cells, which are activated through MHC 517 
complex/TCR and B7/CTLA-4 binding. In responders to treatment, cetuximab-mediated 518 
activation of NK cells induces dendritic cell maturation via crosstalk to promote antigen 519 
presentation and lyse tumor cells through ADCC. However, cetuximab binding also recruits and 520 
expands the Treg population in the tumor microenvironment. These Treg cells inhibit cetuximab-521 
mediated cytotoxicity via expression of immune checkpoint molecules such as PD-1, PD-L1, 522 
CTLA-4, and TIM-3. Upregulation of these immune checkpoint molecules is associated with the 523 
exhausted T cell phenotype, as seen in nonresponders to cetuximab 524 
treatment. Immunosuppressive TGFß is also expressed on Treg cells as well as accumulating 525 
MDSCs, leading to inhibition of cytolytic activity via reduced levels of granzyme B and perforin.  526 
ADCC, antibody-dependent cellular cytotoxicity; APC, antigen presenting cell; CTLA-4, cytotoxic 527 
T lymphocyte-associated antigen 4; EGFR, epidermal growth factor receptor; MDSC, myeloid-528 
derived suppressor cell; MHC, major histocompatibility complex; NK, natural killer; PD-1, 529 
programmed cell death protein 1; PD-L1, programmed death ligand 1; SCCHN, squamous cell 530 
carcinoma of the head and neck; TCR, T cell receptor; TGFß, transforming growth factor ß; 531 
TIM-3, T cell immunoglobulin and mucin-domain containing-3; Treg, regulatory T cell 532 
 533 
Figure 2. (A) OS in patients with prior cetuximab exposure; (B) OS in patients without prior 534 
cetuximab exposure; (C) Treatment effect on OS by baseline subgroups. NA, not available, 535 
minimum follow-up not reached; nivo, nivolumab. 536 
 537 
Figure 3. Changes in the levels of circulating immune cell phenotypes in patients with and 538 
without prior cetuximab exposure in the nivolumab arm. (A) CD8+ effector T cells. CD8+ effector 539 
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T cells were defined as TCRalpha/beta+CD8+CCR7−CD45RA+. (B) Regulatory T cells. 540 
Regulatory T cells were defined as CD4+CD25hiCD127loFoxP3+. Abbreviations: CR, complete 541 
response; IC, investigator’s choice; PD, progressive disease; PR, partial response; SD, stable 542 
disease. 543 
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